Latest news

• Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

  Novo Nordisk has bolstered its biopharma unit with a global licensing deal for a small-molecule drug for genetic blood disorders sickle cell disease and beta thalassaemia. ... And as an oral, once-daily drug EpiDestiny’s candidate could be easier to

• Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

  Buying Bioverativ does give it a stake in advanced approaches for haematological diseases however, as the biotech has an established collaboration with Sangamo Therapeutics looking at genome-editing approaches to beta ... thalassaemia and sickle cell

• Mixed news for gene therapies at ASH conference

  severe beta-thalassaemia (BT), a genetic disorder that causes severe anaemia and organ damage.

• Biogen Idec taps Sangamo for blood disorder drugs

  cell disease (SCD) and beta thalassaemia, and up to $300m in development and commercialisation milestones. ... blood. There are estimated to be around 90, 000 people with SCD in the US and another 2, 000 with beta thalassaemia.

• Bursting the banks

  To determine whether deferiprone and deferoxamine could be used successfully as a combination therapy, a study was carried out in Greece in 36 patients with beta-thalassaemia. ... III trial in 586 patients with beta-thalassaemia and transfusion-related